Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroform SCHEMBL2568782 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL9568279 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL5747359 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL888275 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL48119 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL9037829 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL9526391 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL9525441 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL2571706 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL9528226 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| EP-2044037-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7385063-B2 | Method for preparing imidazole derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-06-10 | — | — | US | disclosed |
| WO-2008016522-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20070185116-A1 | Bicyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | disclosed |
| US-6387948-B1 | ENZYME INHIBITOR | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2002-05-14 | — | — | US | disclosed |
| US-5843735-A | Aklavinone C-11 hydroxylase, gene coding for same, expression vector therefor, and process for preparing hybrid antibiotics by using said vector | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1998-12-01 | — | — | US | disclosed |
| EP-0842195-A1 | PEPTIDE INHIBITORS OF FIBRONECTINE | ZENECA LIMITED (GB) | 1998-05-20 | — | — | EP | disclosed |
| EP-0800535-A1 | FIBRONECTIN ADHESION INHIBITORS | ZENECA LIMITED (GB) | 1997-10-15 | — | — | EP | disclosed |
| WO-1997002289-A1 | PEPTIDE INHIBITORS OF FIBRONECTINE | ZENECA LIMITED (GB) | 1997-01-23 | — | — | WO | disclosed |
| WO-1996020216-A1 | FIBRONECTIN ADHESION INHIBITORS | ZENECA LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |
| US-5358961-A | Hypotensive agents | JIN RO LIMITED (KR) | 1994-10-25 | — | — | US | disclosed |
| US-5166341-A | Selective antagonist of serotonin 3(5-HT3) receptor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLRMT, POLR2H | LMNA 3167/4885TSHR 4747/4885ALDH1A1 2535/4885 |
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | LMNA 1268/4885TSHR 4060/4885ALDH1A1 218/4885 |
| US-20070185116-A1 | Bicyclic compounds | KCNN3, KCNJ1, KCNJ2 | LMNA 3049/4885TSHR 4306/4885ALDH1A1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.